Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aprogen Strikes Third Global Biosimilar Deal With Nichi-Iko

This article was originally published in PharmAsia News

Executive Summary

South Korean biotech firm Aprogen is emerging as another notable player in the increasingly crowded biosimilar space and the company has just reached its third worldwide biosimilar deal since 2014, again with Japan’s Nichi-Iko and this time for its rituximab product.

Advertisement

Related Content

Aprogen/Nichi-Iko's Remicade Biosimilar Clears Japan’s Approval Review
Nichi-Iko Buys Sagent To Strengthen US Biosimilars Presence

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC089389

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel